Phase III clinical trial of L-105 in patients with hepatic encephalopathy
Phase 3
- Conditions
- H.E.
- Registration Number
- JPRN-jRCT2080222041
- Lead Sponsor
- ASKA Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 180
Inclusion Criteria
Subjects of completed the preceding study (L-105/2-A)
Exclusion Criteria
-Grade III or higher hepatic encephalopathy coma level (Coma Level Classification by Inuyama Symposium)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy and safety
- Secondary Outcome Measures
Name Time Method